Benjamin Garmezy

416 total citations
35 papers, 211 citations indexed

About

Benjamin Garmezy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Benjamin Garmezy has authored 35 papers receiving a total of 211 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Benjamin Garmezy's work include Cancer Immunotherapy and Biomarkers (8 papers), Renal cell carcinoma treatment (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Benjamin Garmezy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Renal cell carcinoma treatment (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Benjamin Garmezy collaborates with scholars based in United States, Spain and France. Benjamin Garmezy's co-authors include Moshe Talpaz, John Hicks, Kenneth L. McClain, Philip J. Lupo, Jordan K. Schaefer, Albert J. Shih, Moise L. Levy, Stephen J. Simko, Teresa S. Wright and Karen Phaik Har Lim and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Benjamin Garmezy

31 papers receiving 207 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Garmezy United States	8	84	68	63	55	48	35	211
Vijetha Kumar United States	3	49 0.6×	36 0.5×	95 1.5×	86 1.6×	43 0.9×	6	210
Edgardo R. Parrilla Castellar United States	6	93 1.1×	38 0.6×	48 0.8×	82 1.5×	36 0.8×	9	257
Didem Uzunaslan Türkiye	8	147 1.8×	38 0.6×	31 0.5×	140 2.5×	25 0.5×	12	269
Hirotaka Tsuno Japan	7	35 0.4×	65 1.0×	58 0.9×	34 0.6×	14 0.3×	17	273
Caoimhe Egan United States	6	88 1.0×	24 0.4×	31 0.5×	61 1.1×	16 0.3×	12	189
Alessandro D’Amuri Italy	7	97 1.2×	77 1.1×	66 1.0×	9 0.2×	24 0.5×	12	210
Hisao Higo Japan	10	81 1.0×	46 0.7×	157 2.5×	30 0.5×	36 0.8×	39	211
Maria Pilar García Muret Spain	7	94 1.1×	45 0.7×	32 0.5×	23 0.4×	36 0.8×	14	222
Shee‐Loong Loke Hong Kong	7	229 2.7×	98 1.4×	62 1.0×	20 0.4×	70 1.5×	8	357
Michel Maigre France	6	92 1.1×	55 0.8×	30 0.5×	62 1.1×	20 0.4×	12	200

Countries citing papers authored by Benjamin Garmezy

Since Specialization

Citations

This map shows the geographic impact of Benjamin Garmezy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Garmezy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Garmezy more than expected).

Fields of papers citing papers by Benjamin Garmezy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Garmezy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Garmezy. The network helps show where Benjamin Garmezy may publish in the future.

Co-authorship network of co-authors of Benjamin Garmezy

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Garmezy. A scholar is included among the top collaborators of Benjamin Garmezy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Garmezy. Benjamin Garmezy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gao, Xin, Amita Patnaik, Nehal J. Lakhani, et al.. (2025). NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.. Journal of Clinical Oncology. 43(5_suppl). 2 indexed citations

Reig, Òscar, Laurence Crouzet, Andrea Necchi, et al.. (2024). 652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1. Annals of Oncology. 35. S515–S516. 3 indexed citations

Pal, Sumanta K., Melissa A. Reimers, Benjamin Garmezy, et al.. (2024). A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2676–TPS2676. 4 indexed citations

Chandana, Sreenivasa R, Noura J. Choudhury, Afshin Dowlati, et al.. (2024). First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3001–3001. 10 indexed citations

Garmezy, Benjamin, Mitesh J. Borad, Cesar A. Perez, et al.. (2024). A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer Research Communications. 4(4). 1165–1173. 9 indexed citations

Choueiri, Toni K., Laurence Albigès, Philippe Barthélémy, et al.. (2024). Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. The Lancet. 404(10460). 1309–1320. 32 indexed citations

Garmezy, Benjamin & Ulka N. Vaishampayan. (2024). Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast. Oncology and Therapy. 12(4). 647–661.

Yu, Evan Y., Jason T. Henry, Manish R. Patel, et al.. (2024). Abstract CT068: Interim results of the ongoing phase 1-2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. Cancer Research. 84(7_Supplement). CT068–CT068.

Garmezy, Benjamin, Mitesh J. Borad, L-T. Chen, et al.. (2023). 130P Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations. Annals of Oncology. 34. S231–S232. 1 indexed citations

10.

Voss, Martin H., Benjamin Garmezy, J.P. Maroto Rey, et al.. (2023). 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). Annals of Oncology. 34. S1012–S1012. 7 indexed citations

11.

Gupta, Shilpa, Omar Alhalabi, Aristotelis Bamias, et al.. (2023). 2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo). Annals of Oncology. 34. S1225–S1225.

12.

Chandana, Sreenivasa R, Benjamin Garmezy, Afshin Dowlati, et al.. (2023). 2029TiP Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors. Annals of Oncology. 34. S1077–S1077. 3 indexed citations

13.

Harding, James J., Cesar A. Perez, Shumei Kato, et al.. (2023). P-137 Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations. Annals of Oncology. 34. S63–S64. 1 indexed citations

14.

Motzer, Robert J., Toni K. Choueiri, Benjamin Garmezy, et al.. (2023). Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002. The Oncologist. 28(Supplement_1). S10–S11. 2 indexed citations

15.

Petrylak, Daniel P., Benjamin Garmezy, John Shen, et al.. (2023). 1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations. Annals of Oncology. 34. S973–S974. 4 indexed citations

16.

Brozovich, Ava, Benjamin Garmezy, Tianhong Pan, et al.. (2021). All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. Journal of bone oncology. 31. 100399–100399. 17 indexed citations

17.

Garmezy, Benjamin, Patrick G. Pilié, Wenyi Wang, et al.. (2020). 77P Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors. Annals of Oncology. 31. S270–S270. 1 indexed citations

18.

Garmezy, Benjamin, et al.. (2020). A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Blood Reviews. 45. 100691–100691. 20 indexed citations

19.

Garmezy, Benjamin, Philip S. Boonstra, Malathi Kandarpa, & Moshe Talpaz. (2017). The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System. Blood. 130. 2929–2929. 1 indexed citations

20.

Simko, Stephen J., Benjamin Garmezy, Harshal Abhyankar, et al.. (2014). Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis. The Journal of Pediatrics. 165(5). 990–996. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact